Organ Model: Lung
Applications: Immunology & Inflammation, Cell Therapy
Highlights
This publication establishes a novel Lung-Chip ARDS model for mechanistic and translational evaluation of cell therapies in human-relevant lung tissue. The ARDS model was created by co-culturing NHBE bronchial epithelial cells and HUVEC endothelial cells under flow, inducing injury with LPS in the epithelial channel, and then delivering either primed MSCs or dexamethasone through the vascular channel to compare their effects. The study shows that primed MSCs not only restore endothelial barrier function to near-control levels but also uniquely activate pro-angiogenic pathways and tip-like endothelial programs without signs of uncontrolled proliferation, suggesting they may offer a safer, regenerative alternative to dexamethasone.
